康复新液联合泮托拉唑钠肠溶胶囊治疗消化性溃疡的效果

摘要
图/表
参考文献(25)
相关文章 (15)

全文: PDF (0 KB) HTML (47 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨康复新液联合泮托拉唑钠肠溶胶囊治疗消化性溃疡的效果。方法选取2015年12月～2017年3月就诊于解放军东部战区总医院淮安医疗区的88 例消化性溃疡患者作为研究对象，按照治疗方案的不同将其分为观察组（42 例）和对照组（46 例）。对照组患者予泮托拉唑钠肠溶胶囊治疗，观察组患者采用康复新液联合泮托拉唑钠肠溶胶囊治疗。观察组中，胃溃疡20 例，十二指肠球部溃疡22 例；对照组中，胃溃疡22 例，十二指肠球部溃疡24 例。比较两组患者的各项临床症状（上腹痛、腹胀、嗳气及反酸）改善时间；比较两组患者治疗前后的临床症状评分；比较两组患者的整体治疗效果；比较两组十二指肠球部溃疡、胃溃疡患者的治疗效果；比较两组患者的不良反应发生情况；比较两组愈合患者随访第6 个月及12 个月的溃疡复发率。结果治疗8 周后，观察组患者的上腹痛、腹胀、嗳气及反酸改善时间短于对照组，差异有统计学意义（P＜0.05）。两组患者治疗后的上腹痛、腹胀、嗳气及反酸症状评分低于治疗前，且治疗后观察组患者的上腹痛、腹胀、嗳气及反酸症状评分低于对照组，差异均有统计学意义（P＜0.05）。观察组患者的愈合率及整体治疗总有效率高于对照组，差异有统计学意义（P＜0.05）。治疗后，观察组十二指肠球部溃疡患者、胃溃疡患者的痊愈率及总有效率高于对照组，差异有统计学意义（P＜0.05）。两组患者治疗后的不良反应总发生率比较，差异无统计学意义（P＞0.05）。随访第6 个月及12 个月，观察组患者的溃疡复发率低于对照组，差异有统计学意义（P＜0.05）。结论康复新液联合泮托拉唑钠肠溶胶囊治疗消化性溃疡的效果显著，愈合时间短，复发率低，不良反应少，值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：康复新液, 泮托拉唑钠肠溶胶囊, 消化性溃疡, 效果

Abstract：Objective To investigate the effect of Kangfuxin Liquid combined with Pantoprazole Sodium Enteric Capsules in the treatment of peptic ulcer. Methods A total of 88 patients with peptic ulcer who were treated in Huai′an Medical Area, General Hospital of Chinese People′s Liberation Army Eastern Theater Command from December 2015 to March 2017 were selected as the research subjects, and they were divided into observation group (42 cases) and control group (46 cases) according to different treatment regimen. Control group was treated with Pantoprazole Sodium Enteric Capsules, and observation group was treated with Kangfuxin Liquid combined with Pantoprazole Sodium Enteric Capsules. In the observation group, there were 20 cases of gastric ulcer and 22 cases of duodenal bulb ulcer. In the control group, there were 22 cases of gastric ulcer and 24 cases of duodenal ulcer. The improvement time of various clinical symptoms (epigastric pain, abdominal distention, belching and acid reflux) was compared between the two groups. Clinical symptom scores of two groups were compared before and after treatment. The overall treatment effect of the two groups was compared. The treatment effect of duodenal bulb ulcer and gastric ulcer was compared between the two groups. The incidence of adverse reaction was compared between the two groups. The recurrence rate of ulcer in healed patients was compared between the two groups at 6 and 12 months of follow-up. Results After 8 weeks of treatment, the improvement time of epigastric pain, abdominal distention, belching and acid reflux in the observation group was shorter than that in the control group, with statistical significance (P＜0.05). The scores of epigastric pain, abdominal distention, belching and acid reflux symptoms in the two groups after treatment were lower than those before treatment, and the scores of epigastric pain, abdominal distention, belching and acid reflux symptoms in the observation group were lower than those in the control group after treatment, with statistical significances (P＜0.05). The healing rate and overall effective rate of treatment in observation group were higher than those in the control group, with statistical significances (P＜0.05). After treatment, the cure rate and total effective rate of patients with duodenal bulb ulcer and gastric ulcer in the observation group were higher than those in the control group, and the differences were statistically significant (P＜0.05). There was no significant difference in the total incidence of adverse reaction between the two groups after treatment (P＞0.05). At the 6th and 12th months of follow-up, the recurrence rates of ulcer in healed patients of observation group were lower than those in the control group, and the differences were statistically significant (P＜0.05). Conclusion Kangfuxin Liquid combined with Pantoprazole Sodium Enteric Capsules has a good clinical effect in the treatment of peptic ulcer. It can effectively improve the clinical symptoms, shorten the healing time, reduce the recurrence rate, and have less adverse reactions, which is worthy of clinical promotion and application.

Key words： Kangfuxin Liquid Pantoprazole Sodium Enteric Capsules Peptic ulcer Effect

收稿日期: 2020-12-24

作者简介: 厉琴（1979-），女，汉族，江苏淮安人，本科，副主任医师，研究方向：消化道溃疡及消化道肿瘤

引用本文:

厉琴；李静如；马智慧；张莉；高小花；王莹. 康复新液联合泮托拉唑钠肠溶胶囊治疗消化性溃疡的效果[J]. 中国当代医药, 2021, 28(12): 84-088.
LI Qin LI Jing-ru MA Zhi-hui ZHANG Li GAO Xiao-hua WANG Yin-ying▲. Effect of Kangfuxin Liquid combined with Pantoprazole Sodium Enteric Capsules in the treatment of peptic ulcer. 中国当代医药, 2021, 28(12): 84-088.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I12/84

[1]	葛均波，徐永健.内科学[M].北京：人民卫生出版社，2013：369-374.
[2]	Chen PP，Shen YM，Shi HX，et al.Gastroprotective Effects of Kangfuxin-against Ethanol-Induced Gastric Ulcer via Attenuating Oxidative Stress and ER Stress in Mice[J].Chem Biol Interact，2016，S0009-2797（16）：30 509.
[3]	叶晓敏.康复新在消化性溃疡治疗中的优点[J].临床合理用药杂志，2012，5（5）：88-89.
[4]	张林洁.康复新液联合奥美拉唑、莫沙必利治疗反流性食管炎39 例[J]．中国药业，2012，21（12）：88.
[5]	唐琳，黄启阳，杨云生.消化性溃疡的检查方法及诊断标准[J].医学与哲学（临床决策论坛版），2010，31（5）：16-18，36.
[6]	刘宏伟，黄玉洁，杨剑英，等.含阿莫西林、呋喃唑酮四联疗法治疗幽门螺杆菌相关性胃溃疡的疗效及安全性分析[J].河北医药，2020，42（8）：1169-1172.
[7]	华苗爽，侯雨佳，仝其根.蛋黄油对小鼠消化性胃溃疡的促进愈合作用[J].中国食品学报，2020，20（1）：33-38.
[8]	王淑萍，许焕才，朱洪春.泮托拉唑粉针治疗消化性溃疡并出血的临床观察[J].中国误诊学杂志，2008，8（27）：6609-6610.
[9]	李琳，叶峰，张国新.胃肠道微生态与消化性溃疡关系的研究进展[J].胃肠病学和肝病学杂志，2015，24（3）：241-244.
[10]	杨涛，胡正康.埃索美拉唑联合康复新液治疗老年消化性溃疡的效果[J].临床医学研究与实践，2019，4（12）：11-13.
[11]	王春景.康复新液联合泮托拉唑及哌拉西林舒巴坦钠治疗消化性溃疡的疗效分析[J].中国现代药物应用，2019，13（4）：106-107.
[12]	张晋秀，焦萍，刘清艳，杨红.泮托拉唑钠肠溶胶囊致双下肢水肿1 例[J].中国药物应用与监测，2017，14（5）：321-323.
[13]	孙祥瑞，高家荣，吴健，等.泮托拉唑不良反应中文文献分析[J].安徽医药，2015，19（4）：801-805.
[14]	原瑞桐.泮托拉唑防治危重症患者消化道出血80 例临床观察[J].世界中西医结合杂志，2009，4（12）：886-887.
[15]	颜小丹，周金虎.奥曲肽联合泮托拉唑治疗老年消化性溃疡合并上消化道出血的疗效及对凝血功能和炎症因子的影响[J].中国老年学杂志，2018，38（12）：2902-2904.
[16]	罗金键.泮托拉唑治疗消化性溃疡合并上消化道出血的临床观察[J].中国医院用药评价与分析，2015，15（3）：301-304.
[17]	郭普.泮托拉唑联合枸橼酸铋钾治疗胃溃疡的疗效分析[J].黑龙江医药，2019，32（1）：68-69.
[18]	杨亚莉.奥美拉唑、泮托拉唑、兰索拉唑治疗胃溃疡的疗效及不良反应[J].甘肃医药，2018，37（6）：537-538.
[19]	刘娟，刘小潘.泮托拉唑钠的临床不良反应与合理应用研究[J].首都食品与医药，2018，25（7）：45.
[20]	陈新孚.康复新液联合泮托拉唑治疗消化性溃疡疗效观察及安全性评价[J].临床合理用药杂志，2016，9（26）：54-55.
[21]	李冬梅，吕阳.奥美拉唑联合康复新液治疗慢性萎缩性胃炎疗效分析[J].临床军医杂志，2019，47（11）：1187-1189.
[22]	向正国，郑扬，陈旭峰，等.康复新联合埃索美拉唑治疗消化性溃疡疗效分析[J].世界中西医结合杂志，2013，8（2）：156-158.
[23]	刘艳.泮托拉唑联合康复新液治疗消化性溃疡的临床效果和安全性观察[J].中国医药指南，2018，16（11）：187-188.
[24]	程平，谭丽华，万德惠，等.康复新液联合泮托拉唑治疗消化性溃疡患者的疗效及对GAS、CCK、MTL 水平的影响[J].临床合理用药杂志，2018，11（35）：15-17.
[25]	付茜，魏莹，赵强.康复新液联合泮托拉唑治疗消化性溃疡的效果及对炎症因子水平的影响[J].临床医学研究与实践，2019，4（15）：26-27.